KR20180093925A - 박테리아 감염을 치료하기 위한 비아릴 모노박탐 화합물 및 그의 사용 방법 - Google Patents
박테리아 감염을 치료하기 위한 비아릴 모노박탐 화합물 및 그의 사용 방법 Download PDFInfo
- Publication number
- KR20180093925A KR20180093925A KR1020187016482A KR20187016482A KR20180093925A KR 20180093925 A KR20180093925 A KR 20180093925A KR 1020187016482 A KR1020187016482 A KR 1020187016482A KR 20187016482 A KR20187016482 A KR 20187016482A KR 20180093925 A KR20180093925 A KR 20180093925A
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- tert
- mmol
- alkylene
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 C*c1n[o]c(*C=*)c1 Chemical compound C*c1n[o]c(*C=*)c1 0.000 description 17
- ALLGJVKOLKRAED-LLVKDONJSA-N CC(C)(C)OC([C@@H](COc(cc1)ccc1Br)O)=O Chemical compound CC(C)(C)OC([C@@H](COc(cc1)ccc1Br)O)=O ALLGJVKOLKRAED-LLVKDONJSA-N 0.000 description 1
- OCTMDJLUOWFKSU-SPLIAENESA-N CC(C)([C@@H](C1=O)NC(/C(/c2c[s]c(N)n2)=N\OC(COc2ccc(C(CNC3=NCCN3)N)cc2)C(O)=O)=O)N1OS(O)(=O)=O Chemical compound CC(C)([C@@H](C1=O)NC(/C(/c2c[s]c(N)n2)=N\OC(COc2ccc(C(CNC3=NCCN3)N)cc2)C(O)=O)=O)N1OS(O)(=O)=O OCTMDJLUOWFKSU-SPLIAENESA-N 0.000 description 1
- PPJZYGKFCVMMFK-QXKZAHJASA-O CC(C)([C@@H](C1=O)NC(/C(/c2c[s]c(N)n2)=N\O[C@@H](COc(cc2)ccc2-c2c[n](CCCN)cn2)C(O)=O)=O)N1[OH+]S(O)(=O)=O Chemical compound CC(C)([C@@H](C1=O)NC(/C(/c2c[s]c(N)n2)=N\O[C@@H](COc(cc2)ccc2-c2c[n](CCCN)cn2)C(O)=O)=O)N1[OH+]S(O)(=O)=O PPJZYGKFCVMMFK-QXKZAHJASA-O 0.000 description 1
- UHDWXCYQHAIKOC-PMVWLZOESA-N CC(C)([C@@H](C1=O)NC(/C(/c2c[s]c(N)n2)=N\O[C@@H](COc2ccc(C3NC(NCCN)=NC3)cc2)C(O)=O)=O)N1OS(O)(=O)=O Chemical compound CC(C)([C@@H](C1=O)NC(/C(/c2c[s]c(N)n2)=N\O[C@@H](COc2ccc(C3NC(NCCN)=NC3)cc2)C(O)=O)=O)N1OS(O)(=O)=O UHDWXCYQHAIKOC-PMVWLZOESA-N 0.000 description 1
- SCNJNXZDDYGKMX-LJJQOFDWSA-N CC(C)([C@@H](C1=O)NC(C(c2c[s]c(N)n2)NO[C@@H](COc2ccc(C3CN=C(NCCN)NC3)cc2)C(O)=O)=O)N1OS(O)(=O)=O Chemical compound CC(C)([C@@H](C1=O)NC(C(c2c[s]c(N)n2)NO[C@@H](COc2ccc(C3CN=C(NCCN)NC3)cc2)C(O)=O)=O)N1OS(O)(=O)=O SCNJNXZDDYGKMX-LJJQOFDWSA-N 0.000 description 1
- JKDZRVYDAJBDFO-CQSZACIVSA-N CCOC([C@@H](COc1ccc(B2OC(C)(C)C(C)(C)O2)cc1)O)=O Chemical compound CCOC([C@@H](COc1ccc(B2OC(C)(C)C(C)(C)O2)cc1)O)=O JKDZRVYDAJBDFO-CQSZACIVSA-N 0.000 description 1
- DYSJQUQJVBYIOT-UHFFFAOYSA-N Cc(ccc(C)c1F)c1F Chemical compound Cc(ccc(C)c1F)c1F DYSJQUQJVBYIOT-UHFFFAOYSA-N 0.000 description 1
- HBXFIXSFKULBOG-UHFFFAOYSA-N Cc1cc(F)c(C)c(F)c1 Chemical compound Cc1cc(F)c(C)c(F)c1 HBXFIXSFKULBOG-UHFFFAOYSA-N 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N Cc1ccc(C)nc1 Chemical compound Cc1ccc(C)nc1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- GIWQSPITLQVMSG-UHFFFAOYSA-N Cc1ncc[n]1C Chemical compound Cc1ncc[n]1C GIWQSPITLQVMSG-UHFFFAOYSA-N 0.000 description 1
- JPNFAEKTXXGPCO-UHFFFAOYSA-N NC(C(O)=O)(N)N Chemical compound NC(C(O)=O)(N)N JPNFAEKTXXGPCO-UHFFFAOYSA-N 0.000 description 1
- GZFGOTFRPZRKDS-UHFFFAOYSA-N Oc(cc1)ccc1Br Chemical compound Oc(cc1)ccc1Br GZFGOTFRPZRKDS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
- C07C53/16—Halogenated acetic acids
- C07C53/18—Halogenated acetic acids containing fluorine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562267855P | 2015-12-15 | 2015-12-15 | |
| US62/267,855 | 2015-12-15 | ||
| PCT/US2016/066064 WO2017106064A1 (en) | 2015-12-15 | 2016-12-12 | Biaryl monobactam compounds and methods of use thereof for the treatment of bacterial infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20180093925A true KR20180093925A (ko) | 2018-08-22 |
Family
ID=59057420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020187016482A Ceased KR20180093925A (ko) | 2015-12-15 | 2016-12-12 | 박테리아 감염을 치료하기 위한 비아릴 모노박탐 화합물 및 그의 사용 방법 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20180339983A1 (enExample) |
| EP (2) | EP3978472B1 (enExample) |
| JP (1) | JP7184646B2 (enExample) |
| KR (1) | KR20180093925A (enExample) |
| CN (1) | CN108368040B (enExample) |
| AU (1) | AU2016371600B2 (enExample) |
| CA (1) | CA3008006C (enExample) |
| MA (1) | MA44083A (enExample) |
| MX (1) | MX385731B (enExample) |
| RU (1) | RU2746129C2 (enExample) |
| WO (1) | WO2017106064A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2810003T3 (es) | 2011-11-18 | 2021-03-08 | Regeneron Pharma | Micropartícula que contiene proteína terapéutica recubierta con polímero biodegradable para uso médico |
| MX389242B (es) | 2015-06-15 | 2025-03-20 | Nmd Pharma As | Compuestos para su uso en el tratamiento de trastornos neuromusculares |
| CA3008006C (en) | 2015-12-15 | 2024-04-09 | Merck Sharp & Dohme Corp. | Biaryl monobactam compounds and methods of use thereof for the treatment of bacterial infections |
| SG11202002575UA (en) * | 2017-10-02 | 2020-04-29 | Merck Sharp & Dohme | Chromane monobactam compounds for the treatment of bacterial infections |
| US10385028B2 (en) | 2017-12-14 | 2019-08-20 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US11730714B2 (en) | 2017-12-14 | 2023-08-22 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US12440477B2 (en) | 2017-12-14 | 2025-10-14 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US11591284B2 (en) | 2017-12-14 | 2023-02-28 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US11147788B2 (en) | 2017-12-14 | 2021-10-19 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| CN108362789B (zh) * | 2018-01-19 | 2020-09-01 | 珠海优润医药科技有限公司 | 一种阿维巴坦钠光学异构体的高效液相色谱检测方法 |
| US11459323B2 (en) | 2018-01-29 | 2022-10-04 | Medshine Discovery Inc. | Monocyclic β-lactam compound for treating bacterial infection |
| WO2020048827A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds |
| WO2020048828A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Pharma Aktiengesellschaft | 5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds |
| TW202024068A (zh) * | 2018-11-13 | 2020-07-01 | 大陸商南京聖和藥業股份有限公司 | 單環內醯胺化合物及其應用 |
| CA3121202A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| CN111303144B (zh) * | 2019-12-13 | 2020-11-27 | 苏州信诺维医药科技有限公司 | 一种治疗细菌感染的化合物 |
| US12491180B2 (en) | 2019-12-19 | 2025-12-09 | Shenzhen Optimum Biological Technology Co., Ltd | Application of compound in treating pneumonia |
| EP4007759A4 (en) * | 2020-08-06 | 2024-04-10 | Ningxia Academy of Agriculture and Forestry Sciences | BETA-LACTAM COMPOUNDS, THEIR PREPARATION AND THEIR USE AS ANTIBACTERIAL AGENTS |
| CN112661667B (zh) * | 2020-12-28 | 2023-02-03 | 浦拉司科技（上海）有限责任公司 | 一种三氟乙脒的制备方法 |
| WO2023082055A1 (zh) * | 2021-11-09 | 2023-05-19 | 中国医学科学院医药生物技术研究所 | 包含β-内酰胺类化合物的药物组合物及其用途 |
| CN113975396B (zh) * | 2021-11-09 | 2022-11-29 | 中国医学科学院医药生物技术研究所 | 包含β-内酰胺类化合物的药物组合物及其用途 |
| KR20240105442A (ko) | 2021-11-18 | 2024-07-05 | 머크 샤프 앤드 돔 엘엘씨 | 크로만 아미딘 모노박탐 항생제 |
| JP7671398B2 (ja) * | 2021-11-18 | 2025-05-01 | メルク・シャープ・アンド・ドーム・エルエルシー | クロマンアミジンモノバクタム抗生物質 |
| CN114671910B (zh) * | 2022-04-06 | 2025-03-21 | 河南师范大学 | 一种西多福韦的绿色合成方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4537886A (en) * | 1982-03-31 | 1985-08-27 | Beecham Group P.L.C. | β-lactam antibacterial agents and compositions containing them |
| US4684722A (en) | 1986-01-06 | 1987-08-04 | E. R. Squibb & Sons, Inc. | Monosulfactams |
| ES2373461T3 (es) * | 2005-12-07 | 2012-02-03 | Basilea Pharmaceutica Ag | Antibióticos útiles de monobactama. |
| DK2646436T3 (en) | 2010-11-29 | 2015-06-29 | Pfizer | monobactams |
| UY34585A (es) * | 2012-01-24 | 2013-09-02 | Aicuris Gmbh & Co Kg | Compuestos b-lactámicos sustituidos con amidina, su preparación y uso |
| US8969570B2 (en) * | 2012-03-30 | 2015-03-03 | Cubist Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| US20140275007A1 (en) | 2013-03-14 | 2014-09-18 | Rempex Pharmaceuticals, Inc. | Oxamazin antibiotics |
| US20160326157A1 (en) | 2014-01-06 | 2016-11-10 | President And Fellows Of Harvard College | Monobactams and methods of their synthesis and use |
| WO2015148379A1 (en) * | 2014-03-24 | 2015-10-01 | Novartis Ag | Monobactam organic compounds for the treatment of bacterial infections |
| CA3008006C (en) | 2015-12-15 | 2024-04-09 | Merck Sharp & Dohme Corp. | Biaryl monobactam compounds and methods of use thereof for the treatment of bacterial infections |
-
2016
- 2016-12-12 CA CA3008006A patent/CA3008006C/en active Active
- 2016-12-12 KR KR1020187016482A patent/KR20180093925A/ko not_active Ceased
- 2016-12-12 EP EP21204101.6A patent/EP3978472B1/en active Active
- 2016-12-12 EP EP16876436.3A patent/EP3390357B1/en active Active
- 2016-12-12 MX MX2018005382A patent/MX385731B/es unknown
- 2016-12-12 WO PCT/US2016/066064 patent/WO2017106064A1/en not_active Ceased
- 2016-12-12 RU RU2018123484A patent/RU2746129C2/ru active
- 2016-12-12 MA MA044083A patent/MA44083A/fr unknown
- 2016-12-12 CN CN201680074091.0A patent/CN108368040B/zh active Active
- 2016-12-12 US US15/775,487 patent/US20180339983A1/en not_active Abandoned
- 2016-12-12 JP JP2018530835A patent/JP7184646B2/ja active Active
- 2016-12-12 AU AU2016371600A patent/AU2016371600B2/en active Active
-
2020
- 2020-06-25 US US16/912,146 patent/US11230543B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017106064A1 (en) | 2017-06-22 |
| CA3008006A1 (en) | 2017-06-22 |
| CN108368040A (zh) | 2018-08-03 |
| EP3390357A4 (en) | 2019-06-12 |
| EP3390357B1 (en) | 2021-11-10 |
| CA3008006C (en) | 2024-04-09 |
| RU2018123484A (ru) | 2020-01-17 |
| RU2018123484A3 (enExample) | 2020-03-26 |
| AU2016371600B2 (en) | 2021-02-18 |
| US20200361928A1 (en) | 2020-11-19 |
| AU2016371600A1 (en) | 2018-05-10 |
| CN108368040B (zh) | 2024-08-23 |
| EP3978472B1 (en) | 2024-10-16 |
| US11230543B2 (en) | 2022-01-25 |
| MX2018005382A (es) | 2018-08-16 |
| MA44083A (fr) | 2021-06-02 |
| EP3978472A1 (en) | 2022-04-06 |
| RU2746129C2 (ru) | 2021-04-07 |
| MX385731B (es) | 2025-03-18 |
| JP7184646B2 (ja) | 2022-12-06 |
| BR112018010962A2 (pt) | 2018-12-04 |
| JP2018537483A (ja) | 2018-12-20 |
| US20180339983A1 (en) | 2018-11-29 |
| EP3390357A1 (en) | 2018-10-24 |
| BR112018010962A8 (pt) | 2023-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20180093925A (ko) | 박테리아 감염을 치료하기 위한 비아릴 모노박탐 화합물 및 그의 사용 방법 | |
| KR102408800B1 (ko) | 비시클릭 아릴 모노박탐 화합물 및 박테리아 감염의 치료를 위한 그의 사용 방법 | |
| JP7398391B2 (ja) | Ｎ－［４－オキソ－２，３－ジヒドロ－１，５－ベンズオキサゼピン－３－イル］－５，６－ジヒドロ－４Ｈ－ピロロ［１，２－ｂ］ピラゾール－２－カルボキサミド誘導体及び例えば過敏性腸症候群（ＩＢＳ）を処置するためのＲＩＰ１キナーゼ阻害剤としての関連化合物 | |
| AU2018345523B2 (en) | Chromane monobactam compounds for the treatment of bacterial infections | |
| KR102089878B1 (ko) | 메탈로-베타-락타마제 억제제로서의 3-테트라졸릴-벤젠-1,2-디술폰아미드 유도체 | |
| BR112018010962B1 (pt) | Composto, sal de ácido trifluoroacético, composição farmacêutica, e, uso de um composto | |
| HK40029711B (en) | Chromane monobactam compounds for the treatment of bacterial infections | |
| HK40029711A (en) | Chromane monobactam compounds for the treatment of bacterial infections | |
| BR112020006381B1 (pt) | Composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica | |
| EA044287B1 (ru) | Хроманмонобактамовые соединения для лечения бактериальных инфекций |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-3-3-R10-R17-oth-X000 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R13-asn-PN2301 St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-3-3-R10-R17-oth-X000 |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T13-X000 | Administrative time limit extension granted |
St.27 status event code: U-3-3-T10-T13-oth-X000 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |